Quantum Biopharma (QNTM) Equity Ratio (2021 - 2026)

Quantum Biopharma has disclosed Equity Ratio across 5 years of filings, most recently posting 0.04 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.04, down 89.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.04 (down 89.65% YoY), and the FY2025 annual result was 0.62, down 7.49% from the prior year.
• Equity Ratio came in at 0.04 for Q1 2026 at Quantum Biopharma, down from 0.62 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q3 2024 to a low of 0.04 in Q1 2026.
• The 4-year median for Equity Ratio is 0.62 (2025), against an average of 0.55.
• Across the five-year window, Equity Ratio slipped 7.49% in 2025 and plunged 89.65% in 2026, its largest moves.
• Quantum Biopharma's Equity Ratio stood at 0.8 in 2022, then decreased by 15.66% to 0.67 in 2024, then retreated by 7.49% to 0.62 in 2025, then tumbled by 93.57% to 0.04 in 2026.
• The last three Equity Ratio figures came in at 0.04 (Q1 2026), 0.62 (Q4 2025), and 0.61 (Q3 2025), per Business Quant data.